Graf Akcie NAVB (Navidea Biopharmaceuticals Inc). Diskuze k akciím NAVB. Aktuální informace NAVB.

Základní informace o společnosti Navidea Biopharmaceuticals Inc (Akcie NAVB)

Skvělé pro velmi rychlou analýzu společnosti. Investor může porovnat různé ukazatele s konkurenčními firmami.

Tržní kapitalizace
Hodnota podniku (EV)
Tržby
EBITDA
Zisk
Růst v tržbách Q/Q %
Růst v tržbách Y/Y %
P/E (Cena vůči ziskům)
Forward P/E
EV/Sales
EV/EBITDA
EV/EBIT
PEG
Price/Sales
P/FCF
Price/Book
Účetní hodnota na akcii
Hotovost na akcii
FCF vůči ceně %
Počet zaměstnanců
Tržba na zaměstnance
Profit margin %
Operating margin %
Gross margin %
EBIT margin %
EBITDA margin %
EPS - Zisk na akcii
EPS - Kvartální růst %
EPS - Očekávaný růst příští rok %
Return on assets %
Return on equity %
ROIC %
ROCE %
Dluhy/Equity
Čistý dluh/EBITDA
Current ratio
Quick Ratio
Volatilita
Beta
RSI
Cílová cena analytiků
Známka akcie (dle analytiků)
Insider ownership %
Institutional ownership %
Počet akcií
Procento shortovaných akcií %
Short ratio %
Dividenda
Procentuální dividenda %
Dividenda/Zisk %
Obchodovaná od
Země

Finanční výsledky akcie NAVB

Finanční výsledky společnosti, napoví investorovi, zda se jedná o kvalitní společnost.

# 2020 2019 2018 2017 2016 2015
Revenue$0.658$1.169$1.81$4.972$3.013$6.275
Cost Of Goods Sold$0.007$0.097$0.004$0.062$0.003$1.586
Gross Profit$0.651$1.073$1.807$4.909$3.01$4.689
Research And Development Expenses$5.338$4.222$4.514$7.138$10.563$16.78
SG&A Expenses$6.275$7.698$11.17$7.92$10.888$15.542
Other Operating Income Or Expenses------
Operating Expenses$11.62$12.017$15.687$15.12$21.454$33.908
Operating Income$-10.963$-10.847$-13.877$-10.149$-18.441$-27.633
Total Non-Operating Income/Expense$0.018$-5.321$-3.913$2.771$-4.604$-8.094
Pre-Tax Income$-10.945$-16.169$-17.79$-7.378$-23.045$-35.727
Income Taxes$0.001$-0.01$-4.063---
Income After Taxes$-10.946$-16.159$-13.727$-7.378$-23.045$-35.727
Other Income------
Income From Continuous Operations$-10.946$-16.159$-13.727$-7.378$-23.045$-35.727
Income From Discontinued Operations$-0.003$0.045$88.673$-6.931$-4.519-
Net Income$-10.948$-16.114$74.946$-14.308$-27.609$-35.727
EBITDA$-10.818$-10.697$-13.622$-9.569$-17.376$-26.289
EBIT$-10.963$-10.847$-13.877$-10.149$-18.441$-27.633
Basic Shares Outstanding1498887
Shares Outstanding1498887
Basic EPS$-0.76$-1.89$9.40$-1.80$-3.60$-4.80
EPS - Earnings Per Share$-0.76$-1.89$9.00$-1.80$-3.60$-4.80
# 2020 2019 2018 2017 2016 2015
Current Ratio0.76341.65631.71440.1552.03390.9491
Long-term Debt / Capital----0.16628.7906-92.3078
Debt/Equity Ratio-0.34730.13110.435-0.9103-1.1346-1.1352
Gross Margin98.986591.735999.798398.747799.892974.7222
Operating Margin-1666.477-927.6342-766.5005-204.1329-611.9658-440.3765
EBIT Margin-1666.477-927.6342-766.5005-204.1329-611.9658-440.3765
EBITDA Margin-1644.509-914.7737-752.4382-192.4802-576.6437-418.9507
Pre-Tax Profit Margin-1663.79-1382.696-982.6183-148.3998-764.7473-569.363
Net Profit Margin-1664.3-1378.0244139.667-287.8004-916.2089-569.363
Asset Turnover0.15850.16650.08710.3990.20140.5304
Inventory Turnover Ratio---0.64710.00491.7012
Receiveable Turnover0.729855.28590.222524.48890.81377.015
Days Sales In Receivables500.11516.60211640.66714.9047448.556652.0314
ROE - Return On Equity1242.398-670.3652-113.934510.903442.8054119.8742
Return On Tangible Equity864.3029-815.2916-118.438210.879842.6579119.1512
ROA - Return On Assets-263.6906-230.1325-66.0551-59.2047-153.995-301.9927
ROI - Return On Investment1242.416-670.3624-113.934412.715-333.481811185.2
Book Value Per Share-0.04580.24061.4856-8.6884-6.9175-3.9685
Operating Cash Flow Per Share-1.1514-6.61646.66012.98131.39271.9309
Free Cash Flow Per Share-1.1441-6.61786.65062.98691.54241.9846